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Dose-related effects of ara-C include overcoming a relative transport impediment in human
leukemia cells. This result then allows intracellular metabolism and incorporation into DNA to
proceed to the maximum extent possible. In addition, the increased synthesis ofara-CDP-choline
associated with these high doses may serve as an alternate substrate for phosphatidyl choline
synthesis, which may contribute to membrane fragility and cell lysis.
HiDAC also serves as a "prodrug" for high concentrations ofara-U, which in turn diminishes
ara-C catabolism with a prolonged y phase of systemic clearance and also causes cytostasis in
S-phase with enhanced anabolism andcytotoxicityofsubsequent doses ofara-C. This metabolite/
drug interaction could be termed "self-potentiation," a feature which contributes to the overall
activity of HiDAC. Asparaginase enhances these effects in a schedule-dependent fashion by
lowering the cellular pool size of dCTP and consequent enhanced metabolism of ara-C. The
therapeutic benefit of these pharmacologic manipulations has been verified in a randomized
clinical trial in patients with acute myelogenous leukemia.
The evolution oftherapeutic practice in clinical oncology has been largely based on
empirical trial and error, especially with respect to selection of a drug, its dose,
schedule, and use in combination chemotherapy. Oneofthe hallmarks ofDr. Bertino's
career has been the utilization oflaboratory observations regarding our understanding
of cellular biochemistry, mechanisms of drug action, drug resistance, and drug-drug
interactions in the rational design of therapeutic regimens. This integration of the
laboratory with clinical trials has obviously influenced many of us who trained with
Joe, as is evident in the presentations today. In this regard, I'd like to describe some of
our recent laboratory and clinical investigations with ara-C and asparaginase in acute
leukemia.
Thedepartment ofpharmacology at Yalecontributed a lot to the earlydevelopment
ofcytosine arabinoside (ara-C). Glenn Fischer, Ming Chu, Dick Momparler, Arnold
Welch, Bill Creasy, Rose Papac, and Paul Calabresi, among others, were involved in
studies of the pre-clinical and clinical pharmacology of ara-C as well as in clinical
trials.
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Figure 1 details the cellular pharmacology of ara-C. Chu and Fischer had shown
that in order to exert its effect, ara-C had to be metabolized to the nucleoside,
triphosphate ofarabinosyl cytosine (ara-CTP) [1]. Others then showed that cytotoxic-
ity from ara-C was linked to its incorporation into DNA [2,3]. Subsequently, various
resistance mechanisms in experimental cell lines weredelineated, including diminished
anabolism to ara-CMP mediated by deoxycytidine kinase [4], expanded deoxycytidine
triphosphate (dCTP) pools [5], and short intracellular half-life of ara-CTP [6]. In
these same experimental cell lines, the process ofmembrane translocation or transport
was found to be extremely rapid and, therefore, considered not to be an important
parameter in the cellular pharmacology ofara-C.
Ara-C enters the cell by a carrier-mediated facilitated diffusion mechanism
common to nucleosides [7]. A clear distinction must be made between the physiolog-
ical processes termed transport and uptake. For the present discussion, transport will
refer tothecarrier-mediated membrane translocation ofthedrug. While"uptake" also
invokes "transport," the usual measurements which describe this process primarily
speak to cellular accumulation. Thus, in the present discussion, the term "accumula-
tion" will refer to the intracellular metabolism and retention of ara-C and its
metabolites. While membrane transport of ara-C in experimental tumor models has
been shown to be rapid and not a limiting factor in ara-C metabolism by these cells [8],
it has recently been demonstrated that human leukemia cells taken directly from
patients have, in comparison, very low nucleoside transport activity [9,10].
Over the past several years, as part of a global program of studies of the
pharmacology of ara-C in human leukemia cells, we have been conducting a
prospective study ofara-C transport and metabolism inpatients with acute leukemia at
diagnosis and relapse. These studies intend to relate these pharmacological parameters
to drug response and resistance and, in turn, could be useful for subsequent clinical
trial design.
The number of nucleoside carrier molecules per cell may be directly quantitated by
measuring the binding capacity for the high-affinity inhibitor, nitrobenzyl-mercapto-
purine riboside (NBMPR) [11]. NBMPR is a purine nucleoside analog which binds
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TABLE 1
Ara-C Transport Rate and Nucleoside Carrier Sites
Rate' NBMPR Sites
1. Patients
Acute leukemia 14 + 15 4,223 ± 4,334
n= 45 n=61
2. Human leukemia in cell culture
ML-1 805 139,000
HL-60 49 59,000
CCRF-CEM n.d. 183,000
3. Mouse ascites tumors
Ehrlich 272 94,000
L5178Y 105 74,000
P388 n.d. 137,000
apmol/min/106 cells at 50AM [3H] ara-C ± SD
Maximal specific [3H]NBMPR binding sites per cell ± SD
n.d. = not determined
Reproduced from [13]
tightly to the nucleoside carrier protein (Kd = 0.2 nm) and is not translocated into the
cell [11]. Since NBMPR is a potent inhibitor of transport, relatively moderate
concentrations ofNBMPR, for example, 1 ,uM, will completely block ara-C transport
by this route. Because some experimental cell lines may have significant NBMPR-
insensitive nucleoside transport capacity, NBMPR is also a useful tool for elucidating
alternative transport routes [12].
Transport rates and the number of NBMPR sites, that is, nucleoside carrier
molecules in human leukemic blasts from patients, are contrasted with several murine
and human experimental cell lines in Table 1. Consistent with previous studies, which
indicated that transport was not rate-limiting in ara-C pharmacology, the number of
NBMPR sites and ara-C transport rates are high in both murine and human leukemia
experimental cell lines, including myeloid (HL-60, ML-1) and lymphoblastic (CCRF-
CEM) leukemias. In contrast, the number ofNBMPR binding sites (that is, transport
molecules) and ara-C transport rates in leukemic blasts taken directly from patients is
strikingly lower [13].
To assess the practical relevance oflower transport activity in human leukemia cells,
the transport "control strength" was determined (Fig. 2). Transport control strength,
in essence, is an expression of the role of transport as a determinant of the rate of net
intracellular accumulation ofara-C metabolites. When transport is in great excess and
not a factor ofconsequence, the control strength is zero. When the rate oftransport is
slow and is the sole determinant ofthe rate of net accumulation, control strength is one
[13].
Transport control strength is dependent on the extracellular concentration ofara-C.
The Km for ara-C transport is 400,uM, a value that isquite highcompared toclinically
achievable plasma drug concentrations (see below). Thus, for practical purposes in
everyday therapeutics, the transport rate will be approximately proportional to the
plasma concentration. In contrast, the rate of ara-C phosphorylation intracellularly
approaches a maximal velocity at relatively lower drug levels in the range of 2-5 ,M.
Thus, at concentrations below 1 ,uM, transport may be rate-limiting, but as the
concentration is increased and phosphorylation approaches a maximum, the ratio of
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FIG. 2. Concentration dependence oftransport control strength as a determinant
of the rate of accumulation in AML cells from patients. The solid line is based on
median kinetic constants (refer to Table 2). The dashed and dotted lines are derived
from kinetic parameters of cells from two patients, which represent extremes of high
and low sensitivity to transport capacity as a determinant of the rate of ara-C
accumulation. Solid line, average AML; dashed line, patient 33; dotted line, patient 26
(reproduced from [13]).
transport capacity to phosphorylation capacity increases. At high extracellular concen-
trations, ara-C transport is in excess. This relationship is illustrated by several
examples depicted in Fig. 2. The solid line is based on transport and accumulation data
for 45 patients. This line shows that, for the majority ofpatients, membrane transport
is the rate-limiting process at ara-C concentrations typical of those achieved during
continuous infusion of standard dose ara-C (SDAC), that is, <1.0 ,uM. As the
extracellular concentration of ara-C is increased to the 10-20 ,tM range, however,
transport is less important as a determinant ofthe accumulation rate. As noted below,
the extracellular (plasma) concentrations achieved during short-term infusions of
high-dose ara-C are in considerable excess of these levels. The dashed and dotted
curves illustrate the extremes ofthis process. Transport is the major rate-determining
process for the patient's cells represented by the dashed line up to 8 ,M ara-C. For the
patient's cells represented by the dotted line, transport control strength is always less
than 0.5, indicating that transport only partially determines the rate ofuptake for this
patient even at low ara-C concentrations [13].
The practical message from these studies is that for most patients membrane
transport is the rate-limiting step in the cellular accumulation of ara-C at plasma
concentrations of drug typical of that achieved with standard doses and that this
impediment may be obviated by a suitable increase in dose, which will provide plasma
concentrations above 10 ,uM. At these concentrations, the capacity of the cell to
phosphorylate ara-C and the extent of its incorporation into DNA will be the
determinant features ofara-C cytotoxicity. Thus, any means for enhancing these latter
processes such as the lowering of the competing dCTP pools by biochemical modula-
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TABLE 2
Plasma Levels of Ara-C
,uM Reference
100 mg/M2
Bolus 20.0 [26]
Continuous infusion 0.4 [26]
200 mg/M2
Continuous infusion 0.8 [27]
3,000 mg/M2 100.0 [28]
tion [14,15] or the accumulation of cells in S-phase by the use of cytotostatic agents
[16] may enhance the effects of ara-C. To some extent, these latter mechanisms may
be invoked by uracil arabinoside (ara-U)/ara-C [17,18] and asparaginase (ASNase)/
ara-C interactions [19], as noted below.
For a moment, let us turn to the clinical useofara-C. The sole clinical indication for
ara-C is in the treatment of acute leukemia. In this regard, it is commonly
administered as a continuous infusion or twice daily injection for seven days, at a daily
dosage of 100 to 200 mg/m2, so-called standard dose ara-C (SDAC). Used as a single
agent, this dose and schedule will result in complete remission in 25 percent of
previously untreated patients [20]. Thus, aside from the 20 percent ofpatients who die
during induction, most ofthe patients at presentation may be said to have natural drug
resistance to these doses. Most of the patients who enter remission will eventually
relapse; since response rates are lower in this group of patients, they may be said to
have developed acquired drug resistance.
The introduction of high-dose ara-C (HiDAC) in the treatment of acute leukemia
[21] was based on theoretical assumptions derived from available data on ara-C
pharmacology [22]. These observations questioned whether the plasma concentrations
of ara-C following the administration of standard doses were sufficient to achieve
maximum therapeutic benefit from the drug [22]. The subsequent clinical testing of
these concepts was first conducted here at Yale. This simple study showed that a
15-30-fold dose escalation could elicit a renewed therapeutic response in patients who
were clearly refractory not only to SDAC but also to other antileukemic drugs [21].
This observation lent currency to theory [22]. The utility ofthis therapeutic maneuver
has subsequently been validated by others [23-25]. Given this efficacy of HiDAC
when SDAC has failed raises thequestion as to what the "optimal or standard dose" of
ara-C should be for routine practice.
The cellular pharmacokinetics of ara-C described above (transport and accumula-
tion) are influenced by systemic pharmacokinetics. Plasma drug levels achievable
during bolus and continuous infusion ofvarious doses of ara-C are shown in Table 2.
Bolus injection of 100 mg/m2 results in peak plasma levels of approximately 20 1OM
[26]. Becauseofrapid clearance ofthedrug from plasma, however, this level drops to 1
percent within two hours [26]. Thus, the duration ofexposure of the leukemic cells to
extracellular concentrations ofara-C capable ofovercoming transport deficits (Fig. 2)
would be relatively brief. Continuous infusion of 100 and 200 mg/m2 (SDAC) results
in average plasma steady-state concentrations of0.4 and 0.8 ,uM, respectively [26,27].
Again in consideration of the data relating the effect of transport on cellular
metabolism at various drug concentrations, the plasma steady-state values achieved
15CAPIZZI AND WHITE
120 1E
TT- -T _T>Tara-U
ara-C
. I
30 240 300 360 420 480 540
Time Imin.)
FIG. 3. Plasma ara-C
and ara-U concentrations
during and after a three-
hour infusion of 3 g/m2 ara-
C administered every 12
hours for four doses. Points
represent the mean ± SD of
20 studies in four patients
(A-A = ara-C) and
(-- *= ara-U) (repro-
duced from [28]).
with SDAC would benefit fewer patients, perhaps explaining the observed 25 percent
complete remission frequency associated with the use of SDAC [20]. In contrast,
plasma steady-state levels achieved during infusion of 3 g/m2 for three hours average
between 50 and 100 ,M [28]. This level is considerably in excess of that required to
overcome any transport impediment (Fig. 2) and thus the high levels of ara-C should
rapidly equilibrate across the cell membrane. The main limitations to ara-C effect with
this high dose would be rates of intracellular anabolism and catabolism and the
presence ofcompeting pools ofdCTP and incorporation and retention in DNA.
At theconclusion ofadministration ofara-C, either bolus dose or infusion, the initial
plasma clearance rates (a and d half-lives) are fairly comparable at each dose level.
The plasma clearance of SDAC has been described as a bi-exponential process [29].
With infusions of high-dose ara-C at 3 g/m2, however, most patients display a
tri-exponential process with an additional y half-life ofsix hours (Fig. 3) [28]. Shortly
after the start of infusion, ara-C is rapidly deaminated to ara-U, which is relatively
nontoxic. During HiDAC infusion, the plasma concentration of ara-U is two to three
times higher than ara-C, ranges between 200 and 300 ,tM, and displays a mono-
exponential half-life of 3.75 hours (Fig. 3) [28]. Clinical and laboratory observations
suggest that the extent of this deamination process is dose-dependent. Ho and Frei
measured the ara-U/ara-C ratio in plasma following various doses ofara-C. At doses
ranging from 47 to 200 mg/M2, the ara-U/ara-C ratio at five minutes after drug
administration was 2.6 to 1.4, respectively [30]. In contrast, this ratio dropped to 0.3
following 1,500-3,000 mg/M2 [30]. Following up this lead, we studied the effect of
high concentrations of exogenous ara-U on ara-C catabolism in vitro and in vivo. A
Lineweaver-Burk plot (Fig. 4) illustrates this interaction in vitro. The addition of
increasing concentrations of ara-U retarded the activity of cytidine deaminase on
ara-C. The enzyme was derived from human leukemia cells [28]. With continuous
infusion in mice, ara-U is concentrated in the liver and kidneys; assay ofCR deaminase
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FIG. 4. Lineweaver-Burk plot indi-
cating the inhibitory effect of ara-U on
purified cytidine deaminase derived
from human AML cells. The enzyme
assays were performed as described in
materials and methods, using 0.7 unit
ofpurified Cyd deaminase and the indi-
cated concentrations of ara-U. The
insert (B) shows a replot of the slope of
the lines obtained from the double
reciprocal plot(A)versus ara-U concen-
tration (reproduced from [28]).
activity in these organs shows decreased activity following ara-U infusion [18]. The
plasma clearanceofara-C administered after infusion ofara-U for 48 hours is retarded
relative to saline-infused mice [18]. We conjecture that a similar occurrence in man
contributes to the observed y phase.
The most successful clinical reports of the use of high-dose ara-C utilize 6-12
consecutive doses [31]. Given the relatively long plasma half-life for ara-U [28], the
repetitive doses of HiDAC at 12-hour intervals, in essence, mimic a continuous
infusion oflarge doses ofara-U. We thus decided to explore the direct effects ofara-U
on murine leukemia cells. When exposed to high concentrations of ara-U, that is,
lO-5-1O-' M, the growth of L5178Y cells was delayed. DNA histogram analysis of
these growth-inhibited cells revealed accumulation in the S-phase of the cell cycle
(Fig. 5). Studies with these cell populations showed an overall increase in the specific
activity of the S-phase enzyme deoxycytidine (dCyd) kinase and, consequently,
exposure ofthe cells to ara-C after ara-U pretreatment for 24-48 hours was associated
with increased ara-CTP and ara-C DNA formation, with a consequent increase in
ara-C cytotoxicity [17]. Similar effects have been noted in vivo with the continuous
infusion oflarge doses ofara-U, followed by ara-C treatment [18].
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One ofthe most striking features associated with the clinical use of high-dose ara-C
is the rapid lysis of leukemia cells. Within 72-96 hours of having started HiDAC
therapy, the peripheral blood count has commonly been reduced to 1 percent of its
original number. This clinical observation raised a question regarding the mecha-
nism(s) of ara-C cytotoxicity. Ifara-C destroys cells only subsequent to its incorpora-
tion into DNA, 99 percent of the cells will not have all traversed S-phase during this
time [32]. Review of the metabolism of ara-C suggests the possible implication of a
heretofore trivial metabolite ofara-C, arabinosyl cytosine diphosphocholine (ara-CDP
choline) [33,34] in this cell lysis mechanism. Ara-CTP can serve as a substrate in the
synthesis of ara-CDP-choline. The subsequent utilization of ara-CDP-choline as a
substrate for, or as an analog inhibitor in, the synthesis of phosphatidyl choline may
cause sufficient imbalance in phospholipids in the cell membrane to result in
membrane fragility. We are pursuing this hypothesis with current laboratory studies
[35].
Well, what does all of this have to do with current therapeutics? As mentioned
earlier, the prime clinical indication for ara-C is in the treatment ofacute leukemia. In
this regard, new drugs enter clinical trials by first being tested in a phase II fashion in
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TABLE 3
Phase II Trials of New Drugs in the Treatment of Relapsed and Refractory
Acute Leukemia
No. Patients % CR
VP-16 96 18
m-AMSA 327 16
Mitoxantrone 153 18
Rubidazone 200 40
Aclacinomycin 219 24
5-Azacytidine 151 21
High-dose Ara-C 420 25
Reproduced from [31] and [36]
patients with relapsed and refractory acute myelogenous leukemia (AML). Review of
response rates of some newly introduced drugs reveals overall response rates in the
15-20 percent range [36]. In this setting, review ofhigh-dose ara-C efficacy in patients
who were either refractory or who had relapsed from SDAC therapy revealed response
rates in the 25 percent range following the use ofHiDAC; that is, response rates equal
to thoseofnewly introduced drugs (Table 3) [31]. This renewed responsefrom HiDAC
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FIG. 6. CALGB protocol 8121 usingsequential high-doseara-C (HiDAC) andasparaginase
(ASNase) or HiDAC alone: 3 g/m2 ofara-C was added to 500 cc ofpreservative-free saline and
infused intravenously over three hours. The dose was repeated every 12 hours for four doses.
Three hours after the completion of the fourth dose, a single intramuscular injection of 6,000
IU/m2 ASNase was administered. The same treatment was repeated ondays 8 and 9. By random
allocation, an equivalent group received the same dose and schedule of HiDAC without the
ASNase (reproduced from [38]).
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TABLE 4
Complete Remission Rates According to Prior Response and Age in Adults With Refractory and
Relapsed AML
Refractory Relapsed
Age (years) HiDAC/ASNase HiDAC HiDAC/ASNase HiDAC
<60 54% 18% 37% 33%
_60 31% 0% 43% 21%
Reproduced from [38]
in patients who had already failed therapy with lower doses of ara-C may invoke
dose-response relationships such as membrane transport, altered pharmacokinetics,
ara-U/ara-C interactions, and possibly alternate mechanisms of action such as
interference with cell membrane integrity.
Our prior laboratory data indicate that high-dose ara-C is potentiated by the protein
synthesis inhibitor asparaginase in a schedule-dependent fashion [37]. Since asparagi-
nase does not have substantial utility in the treatment ofAML, we proposed a study to
the national cooperative group, the Cancer and Leukemia Group B (CALGB), which
compared, by random allocation, the remission induction potential ofHiDAC alone vs.
HiDAC with sequential ASNase (Fig. 6). This study included 195 adult patients with
refractory and relapsed AML, all of whom had failed therapy with SDAC, an
anthracycline antibiotic, with and without other drugs. This randomizing study
demonstrated a superior response rate for HiDAC/ASNase compared to HiDAC
alone for patients with refractory AML (Table 4). Response rates for relapsed patients
less than 60 years of age were comparable with the two arms. There was, however, a
higher response frequency from HiDAC/ASNase for relapsed patients over 60 years
of age compared to HiDAC alone [38]. Given these response rates in failed patients,
we were eager to test this in newly diagnosed patients. Results to date indicate that the
complete remission rates in patients with newly diagnosed AML equal those of
ara-C/anthracycline combinations, again suggesting an improvement in response over
standard doses [39]. This finding would suggest that the subsequent inclusion of
another active drug, such as an anthracycline, has the potential for further improve-
ments.
The mechanism ofASNase-potentiation of HiDAC is under exploration in L5178Y
cells. Asparaginase alters the cellular pool size of cytidine triphosphate (CTP) and
dCTP in a schedule-dependent fashion. While we do not have definitive data, our
hypothesis is that the decrease in CTP may be related to the glutaminase effect of
ASNase with lowered glutamine pools and subsequent effect on the activity of CTP
synthetase. The administration of ara-C during this period of lower CTP and dCTP
pools is associated with increased ara-CTP, ara-C DNA, and ara-CDP-choline
synthesis [19]. This area requires further investigation.
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